IL-2, Its Receptors, and bcl-2 and bax Genes in Normal, Hyperplastic and Carcinomatous Human Prostates: Immunohistochemical Comparative Analysis

References

• Addison C. L., Bramson J. L., Hitt M. M., Muller W. J., Gauldie J., Graham F. L. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy 1998; 5: 1400–1409
   PubMed Web of Science ®Google Scholar
• Aihara M., Scardino P. T., Truong L. D., Wheeler T. M., Goad J. R., Thompson T. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 1995; 75: 522–529
   PubMed Web of Science ®Google Scholar
• Akbar A. N., Borthwick N. J., Wickremasinghe R. G., Panayoitidis P., Pilling D., Bofill M., Krajewski S., Reed J. C., Salmon M. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol 1996; 26: 294–299
   PubMed Web of Science ®Google Scholar
• Bonkhoff H., Fixemer T., Remberger K. Relation between bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998; 34: 251–258
   PubMed Web of Science ®Google Scholar
• Bostwick D. G., Cooner W. H., Denis L., Jones G. W., Scardino P. T., Murphy G. P. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992; 70: 291–301
   PubMed Web of Science ®Google Scholar
• Bubendrof L., Sauter G., Moch H., Jordan P., Blöchlinger A., Gasser T. C., Mihatsch M. J. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am. J. Pathol 1996; 148: 1557–1565
   PubMed Web of Science ®Google Scholar
• Colombel M., Symmans F., Gil S., O'Toole M., Chopin D., Benson M., Olsson C. A., Korsmeyer S., Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol 1993; 143: 390–400
   PubMed Web of Science ®Google Scholar
• De Miguel M. P., Royuela M., Bethencourt F. R., Ruiz A., Fraile B., Paniagua R. Immunohistochemical comparative analysis of transforming growth factor α, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 1999; 11: 722–727
   PubMed Web of Science ®Google Scholar
• De Miguel M. P., Royuela M., Bethencourt F. R., Santamararia L., Fraile B., Paniagua R. Immunoexpression of tumor necrosis factor-α and its receptors 1 and 2correlates with proliferation/apoptosis equilibrium in normal, hyperplastic and carcinomatous human prostate. Cytokine 2000; 12, (in press)
   PubMed Web of Science ®Google Scholar
• Greene W. C., Depper J. M., Kronke M., Leonard W. J. The human interleukin-2 receptor: analysis of structure and function. Immunol. Rev 1986; 92: 29–48
   PubMed Web of Science ®Google Scholar
• Johnson M., Robinson M. C., Marsh C., Robson C., Neal D. E., Hamdy F. C. Expression of bcl-2, bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 1998; 37: 223–229
   PubMed Web of Science ®Google Scholar
• Kayser K., Bubenzer J., Kayser G., Eichhorn S., Zemlyanukhina T. V., Bovin N. V., Andre S., Koopmann J., Gabius H. J. Expression of lectin, interleukin-2 and histopathologic blood group binding sites in prostate cancer and its correlation with integrated optical density and syntactic structure analysis. Anal. Quant. Cytol. Histol 1995; 17: 135–142
   PubMed Web of Science ®Google Scholar
• Krajewska M., Krajewski S., Epstein J. I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J. C. Immunohistochemical analysis of bcl-2, bax, bcl-x and mcl-1 expression in prostate cancer. Am. J. Pathol 1996; 148: 1567–1576
   PubMed Web of Science ®Google Scholar
• Krajewski S., Tanaka S., Takayama S., Schibler M. J., Fenton W., Reed J. C. Investigation of the subcellular distribution of the bcl-e oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993; 53: 4701–4714
   PubMed Web of Science ®Google Scholar
• Kyprianou N., Tu H., Jacobs S. C. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum. Pathol 1996; 27: 668–675
   PubMed Web of Science ®Google Scholar
• Lode H. N., Xiang R., Becker J. C., Gillies S. D., Reisfeld R. A. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther 1998; 80: 277–292
   PubMed Web of Science ®Google Scholar
• Maffezzini M., Simonato A., Fortis C. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 1996; 28: 282–286
   PubMed Web of Science ®Google Scholar
• Mantovani G., Maccio A., Astara G., Contini L., Esu S., Littera S., Arangino V., Lai P., Proto E., Pusceddu G. Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies. Cell. Biophys 1993; 22: 79–99
   PubMedGoogle Scholar
• Marx D., Binder C., Meden H., Lenthe T., Ziemek T., Hiddemann T., Kuhn W., Schauer A. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997; 17: 2233–2240
   PubMed Web of Science ®Google Scholar
• Matalliotakis I., Sifakis S., Goumemou A., Fragouli Y., Neonaki M., Matalliotakis G., Koumantakis E. Cytokine levels in seminal plasma. Clin. Exp. Obis. Gyn 1998; 25: 58–60
   PubMedGoogle Scholar
• McDonnell T., Troncoso P., Brisbay S. M., Logothetis C., Chung L., Hsieh J., Tu S., Campbell M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940–6944
   PubMed Web of Science ®Google Scholar
• Minami Y., Kono T., Yamada K., Kobayashi N., Kawahara A., Perlmutter R. M., Taniguchi T. Association of p56Ick with IL-2 receptor β chain is critical for the Il-2-induced activation of p56lck. EMBO J 1993; 12: 759–768
   PubMed Web of Science ®Google Scholar
• Miyashita T., Drajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D., Hoffmann B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and, in vivo. Oncogene 1994; 9: 1799–1805
   PubMed Web of Science ®Google Scholar
• Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Oomens E. H., Van Sttenbrugge G. J., Van der Kwast T. H., Schroder F. H. Application of the mononuclear antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma. J. Urol 1991; 145: 81–85
   PubMed Web of Science ®Google Scholar
• Reed J. C. Bcl-2 and the regulation of programmed cell death. J. Cell. Biol 1994; 124: 1–6
   PubMed Web of Science ®Google Scholar
• Royuela M., De Miguel M. P., Ruiz A., Fraile B., Arenas M. I., Romo E., Paniagua R. Interferon-γ and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur. Cytokine Network 2000; 11: 119–127
   PubMed Web of Science ®Google Scholar
• Shi Y., Wang R., Sharma A., Gao C., Collins M., Penn L., Mills G. B. Dissociation of cytokine signals for proliferation and apoptosis. J. Immunol 1997; 159: 5318–5328
   PubMed Web of Science ®Google Scholar
• Staunton M. J., Gaffney E. F. Apoptosis. Basic concepts and potential significance in human cancer. Arch. Pathol. Lab. Med 1998; 122: 310–319
   PubMed Web of Science ®Google Scholar
• Takeshita T., Aso H., Ahtani K., Ishii N., Kumaki S., Tanaka N., Munakata H., Nakamura M., Sugamura K. Cloning of the y chain of the human IL-2 receptor. Science 1992; 257: 379–382
   PubMed Web of Science ®Google Scholar
• Theze J., Aizari P. M., Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol. Today 1996; 17: 481–486
   PubMedGoogle Scholar
• Triest J. A., Grignon D. J., Cher M. L., Kocheril S. V., Montecillo E. J., Talati B., Tekyi-Mensah S., Pontes J. E., Hiliman G. G. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model. Clin. Cancer Res 1998; 4: 2009–2014
   PubMed Web of Science ®Google Scholar
• Wyllie A. H. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastasis Rev 1992; 11: 95–103
   PubMed Web of Science ®Google Scholar